Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast.
Nassr
Nassr
N
Department of Exploratory Medicine, ALTANA Pharma AG, Byk-Gulden-Str. 2, 78467 Konstanz, Germany.
Lahu
Gezim
G
Hünnemeyer
Andreas
A
von Richter
Oliver
O
Knoerzer
Dietrich
D
Reutter
Felix
F
Zech
Karl
K
Hermann
Robert
R
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000328:Adult; D000536:Aluminum Hydroxide / Q000009:adverse effects / Q000494:pharmacology*; D000631:Aminopyridines / Q000097:blood / Q000493:pharmacokinetics*; D000863:Antacids / Q000009:adverse effects / Q000494:pharmacology*; D001549:Benzamides / Q000097:blood / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D003521:Cyclopropanes / Q000097:blood / Q000493:pharmacokinetics; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008276:Magnesium Hydroxide / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*
D000631:Aminopyridines; D000863:Antacids; D001549:Benzamides; D003521:Cyclopropanes; D010726:Phosphodiesterase Inhibitors; C424423:Roflumilast; D000536:Aluminum Hydroxide; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; C517734:roflumilast N-oxide; D008276:Magnesium Hydroxide